CSBio CSBio

X
[{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Signet","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Signet Healthcare Partners Completes Growth Equity Investment in Juno Pharmaceuticals Corp.","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Juno Pharmaceuticals Pty Ltd"},{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Juno Pharmaceuticals Receives Approval to Import Eptifibatide as Canadian Hospitals Continue to Grapple with Shortages of Critical Medicines","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Peptide","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Juno Pharmaceuticals Pty Ltd"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa.

            Lead Product(s): Eptifibatide

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 30, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Juno intends to use these proceeds to expand its complex and high-value generic and biosimilar portfolio including Adrenaline Aguettant. Signet will further enhance Juno’s already strong growth profile given their extensive experience in pharma, and specifically with generics.

            Lead Product(s): Epinephrine

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Adrenaline Aguettant-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Signet

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing February 24, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY